SquamousCellCarcinomaofSkin near Tarrytown, NY

Biography: Samuel Yamshon, M.D. is an Assistant Professor of Medicine at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Yamshon cares for patients with blood cancers with a specific focus on lymphoma and improving outcomes for patients using innovative treatments like cellular immunotherapies including CAR T-cell therapy.Dr. Yamshon received his B.A. from Columbia University and completed his medical training at the University of California, Davis. He returned to New York to train in Internal Medicine at Weill Cornell Medicine, where he also completed his fellowship in Hematology and Oncology. At Weill Cornell Medicine, he specializes in treating patients with lymphoma using cellular therapies including bone marrow transplantation and CAR T cell therapy, and is involved in clinical research dedicated to improving outcomes for patients with lymphoma. He has been involved in lymphoma research for over a decade, co-authoring numerous publications and several presentations at national meetings. Dr. Yamshon is also an Editorial Fellow for the journal Leukemia & Lymphoma. He has received multiple research grants including the American Society of Clinical Oncology (ASCO) Young Investigator Award and the Lymphoma Research Foundation (LRF) Scientific Research Mentoring Program.

Biography: Dr. Chris Hackett received his BS in Biological Sciences from Stanford University in 2000. After doing biomedical research in industry and academia, he then pursued graduate studies in cancer genomics at the University of California, San Francisco, where he earned his PhD in 2010. Seeking to become a physician-scientist, he then earned his medical degree (MD) from the University of Minnesota in 2014. He then completed his Internal Medicine Residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center (MSK), where he focused on solid tumor oncology in the clinic and carried out laboratory research to design T cell therapies for cancer. Following fellowship, Dr. Hackett was an attending on the Cellular Therapeutics Service at MSK, where he focused on treating patients with CAR T cells, Tumor Infiltrating Lymphocytes (TIL) and other cell therapies. In 2023, he joined the Bone Marrow Transplant Service at Weill Cornell Medicine and NewYork-Presbyterian Hospital, where he continues to both treat patients with cellular therapies and conduct research to develop new cell therapies for solid tumors.